Midland Wealth Advisors LLC owns $2.48M in Johnson & Johnson (NYSE:JNJ)

Midland Wealth Advisors LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,954 shares of the company’s stock after selling 553 shares during the period. Midland Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $2,478,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Vestmark Advisory Solutions Inc. raised its holdings in shares of Johnson & Johnson by 12.7% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 19,587 shares of the company’s stock valued at $3,070,000 after purchasing an additional 2,201 shares in the last quarter. Meridian Financial Partners LLC bought a new stake in Johnson & Johnson in the second quarter valued at $1,626,000. Summit Financial Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 26.3% in the first quarter. Summit Financial Wealth Advisors LLC now owns 5,392 shares of the company’s stock valued at $853,000 after buying an additional 1,122 shares in the last quarter. Gilbert & Cook Inc. lifted its position in shares of Johnson & Johnson by 3.3% in the fourth quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock worth $1,428,000 after buying an additional 288 shares during the last quarter. Finally, Franklin Parlapiano Turner & Welch LLC raised its stake in shares of Johnson & Johnson by 0.7% in the first quarter. Franklin Parlapiano Turner & Welch LLC now owns 47,186 shares of the company’s stock worth $7,464,000 after acquiring an additional 325 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s shares.

Insider buying and selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible via this hyperlink. 0.16% of shares are owned by corporate insiders.

Johnson & Johnson stocks rose 0.1%

Shares of JNJ stock opened at $167.27 on Thursday. The stock has a market cap of $402.57 billion, a P/E ratio of 10.43, a price-to-earnings-growth ratio of 2.73 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07, and a quick ratio of 0.85. The stock has a fifty day moving average price of $156.82 and a 200 day moving average price of $153.70. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same period in the prior year, the business earned $2.80 EPS. The company’s revenue rose 4.3% year-over-year. analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a dividend of $4.96 on an annualized basis and a dividend yield of 2.97%. Johnson & Johnson’s payout ratio is currently 30.92%.

Analyst upgrades and downgrades

A number of brokerages have recently weighed in on JNJ. Morgan Stanley upped their target price on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $160.00 to $150.00 in a research report on Tuesday , July 23. Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 30th. Goldman Sachs Group dropped their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Finally, Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $173.21.

Get the latest research report on Johnson & Johnson

About Johnson & Johnson

(Free report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

Read more

Want to see what other hedge funds JNJ owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Free Report).

Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.